CoChat

A Phase II Study of Troglitazone, an Activator of the PPAR?? Receptor, in Patients with Chemotherapy-Resistant Metastatic Colorectal Cancer

Kulke, Matthew H., Demetri, George D., Sharpless, Norman E., Ryan, David P., Shivdasani, Ramesh, Clark, Jeffrey S., Spiegelman, Bruce M., Kim, Haesook, Mayer, Robert J., Fuchs, Charles S. · 2002 · The Cancer Journal
Cited by 150

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

PURPOSE: Troglitazone, a potent activator of the peroxisome proliferator-activated receptor-gamma, induces tumor differentiation in human liposarcomas and causes regression of tumors that are derived from human colon cancer cells in nude mice. We therefore assessed the efficacy of troglitazone in the treatment of metastatic colon cancer in humans. METHODS: Twenty-five patients with metastatic colorectal cancer were treated with oral troglitazone. Patients were followed up for evidence of toxicity, tumor response, and survival. RESULTS: The treatment was well tolerated: no grade 3/4 treatment-related toxicities were observed. However, no objective tumor responses were noted, and all 25 patients had progressive disease as their best response to therapy. The median progression-free survival time was only 1.6 months, and the median survival time was 3.9 months. DISCUSSION: Troglitazone is not an active agent for the treatment of metastatic colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00130404-200209000-00010

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 150

Metadata

Authors
Kulke, M. H., Demetri, G. D., Sharpless, N. E., Ryan, D. P., Shivdasani, R., Clark, J. S., Spiegelman, B. M., Kim, H., Mayer, R. J., & Fuchs, C. S.
Venue
The Cancer Journal
Published
2002-09
Volume
8
Issue
5
Pages
395-399
ISSN
1528-9117 (ISSN-L)
OpenAlex
W2056734036
Cited by
150
References
2
FWCI
2.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase II Study of Troglitazone, an Activator of the PPAR?? Receptor, in Patients with Chemotherapy-Resistant Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1097/00130404-200209000-00010
The paper
Kulke, M. H., Demetri, G. D., Sharpless, N. E., Ryan, D. P., Shivdasani, R., Clark, J. S., Spiegelman, B. M., Kim, H., Mayer, R. J., & Fuchs, C. S. (2002). A Phase II Study of Troglitazone, an Activator of the PPAR?? Receptor, in Patients with Chemotherapy-Resistant Metastatic Colorectal Cancer. The Cancer Journal. https://doi.org/10.1097/00130404-200209000-00010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.